Award

Risk of Clonal Hematopoiesis of Indeterminate Potential in Patients with Acute Coronary Syndromes – Linking Mutagenesis and Inflammation with Atherothrombosis

Description: Background and rationaleClonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by the presence of somatic mutations in leukemia driver genes in individuals without hematological abnormalities. It is associated with the development of malignancies and atherosclerotic cardiovascular (CV) disease. All conditions share increased chronic inflammation as a key driver in their pathogenesis. The CANTOS trial showed that anti-interleukin 1ß (IL1ß) therapy lowered CV events, lung cancer occurrence and mortality, suggesting a derailed response to chronic injury as trigger of both diseases. Mouse experiments have demonstrated a cause-effect relationship between a bone marrow-derived loss-of-function mutation in the TET2 gene and increased pro-inflammatory cytokines, including IL1ß, and atherosclerosis. Atherosclerosis and thrombosis – both associated with inflammation – are central drivers of acute coronary syndromes (ACS). Yet, the value of CHIP and its inflammatory fingerprint for risk prediction in patients with ACS is unknown and the causal role of XY, a frequently mutated gene in CHIP, also remains to be investigated in the context of atherothrombosis.Hypothesis and specific aimsWe hypothesize that CHIP mutations predict CV events in patients with ACS and enhance atherothrombosis.We will test this hypothesis by addressing the following specific aims:Aim 1: Determine the risk for CV events of CHIP mutations in ACS patients (SPUM-ACS cohort, n>5’000). We will analyze whole blood genomic DNA for CHIP (mutation, clone size) from of ACS patients with major adverse CV events (MACE: myocardial infarction, stroke, CV death at 1y=cases, n=400) matched (age, sex, T2D) 2:1 to controls (no MACE).Aim 2: Assess inflammation for risk prediction in ACS patients (SPUM-ACS cohort, n>5’000). We will create a ranking of inflammatory markers focusing on candidates that have been associated with CHIP in vitro. This set of candidates will be expanded using focused proteomic screening (OLINK, case-control analysis from 2’000 ACS patients) and pathway analyses. The most promising candidate markers will be validated in the case-control setting described above for Aim 1. These inflammatory markers will be ranked for CHIP and CV risk factors and be related to CV outcomes.Aim 3: Characterize the effects of loss-of-function (LOF) of a frequently mutated gene XY in CHIP using mouse models of atherosclerosis and carotid artery thrombosis. We will transplant bone marrow cells from XY+/+ or bone marrow-specific XY-/- mice into XY+/+ (thrombosis) or XY+/+-Ldlr-/- (atherosclerosis) recipient mice. Protagonists include monocyte/macrophages, neutrophils, inflammatory cytokines and defense mechanisms (e.g. NETS).Expected results and impactWe anticipate that our results will provide a valuable tool for risk stratification in patients with ACS and mechanistic insight into CHIP as a potential driver of arterial thrombosis and atherosclerosis. Our findings may help to refine strategies for secondary prevention, such as more aggressive lipid-lowering or specific anti-inflammatory therapies.The concept of “chronic injury' (age, toxins, smoking etc) leading to increased mutagenesis, CHIP, and an 'enhanced inflammatory response to injury” can be extended to other chronic (auto-) inflammatory diseases.
Amount: CHF 474,000
Funding type: research
Funder scheme: Project funding
Start date: 2020-10-01
End date: 2025-09-30
Investigator: Matter, Christian M. (lead)
Institutions: University of Zurich, University of Zurich – ZH
Subfield: Hematology
Field: Medicine
Funded outputs count: 1
Funder award ID: 189229
OpenAlex ID: G6686219269
2020 · Sokrates Stein, Julien Weber, et al. · Cardiovascular Research · 52